Pseudomonas Patents (Class 435/252.34)
-
Publication number: 20140335125Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become ‘killed but metabolically active’.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Applicants: UNIVERSITE JOSEPH FOURIER - GRENOBLE 1, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLEInventors: Audrey Le Gouellec, Bertrand Toussaint, Benoît Polack
-
Publication number: 20140329250Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 30, 2014Publication date: November 6, 2014Inventors: Satoshi INOUYE, Yuiko SAHARA
-
Publication number: 20140328801Abstract: A non-therapeutic method of accumulating a polymeric or high molecular weight molecular product within a bacterial microcompartment in bacterial cytoplasm, which method employs a recombinant bacteria which is transformed to express a microcompartment containing an enzyme capable of converting a low molecular weight substrate into a polymeric or high molecular weight product, the method comprising the steps of: incubating the recombinant bacteria with the low-molecular weight substrate, or a precursor of the low molecular weight substrate which is capable of being metabolised to the substrate within the recombinant bacteria, such that the substrate or precursor is taken up by the bacteria, wherein the substrate enters the microcompartment and the enzyme within the microcompartment converts the substrate to a polymeric or high molecular weight molecular product, and wherein the polymeric or high molecular weight molecular product is accumulated within the microcompartment due to its size.Type: ApplicationFiled: September 27, 2012Publication date: November 6, 2014Inventors: Michael Prentice, Martin Warren, Mingzhi Liang
-
Publication number: 20140331364Abstract: Provided are isolated polypeptides having beta-glucosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 19, 2012Publication date: November 6, 2014Inventors: Ye Liu, Junxin Duan, Yu Zhang, Lan Tang
-
Publication number: 20140328797Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.Type: ApplicationFiled: April 28, 2014Publication date: November 6, 2014Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
-
Publication number: 20140329916Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. Also provided herein are methods for using such an organism to produce adipate, 6-aminocaproate, hexamethylenediamine or caprolactam.Type: ApplicationFiled: December 16, 2013Publication date: November 6, 2014Applicant: Genomatica, Inc.Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
-
Publication number: 20140322768Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140322770Abstract: The present invention relates to isolated polypeptides having peroxygenaseactivity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140323348Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
-
Publication number: 20140322224Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Applicant: ALPER BIOTECH LLCInventor: Ozge Alper
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140325711Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 23, 2012Publication date: October 30, 2014Inventors: Kirk Matthew Schnorr, Jens Erik Nielsen, Mikkel Klausen
-
Publication number: 20140322221Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.Type: ApplicationFiled: March 28, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Kathy L. MILLER, Leonard G. PRESTA
-
Publication number: 20140322812Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Applicant: Intrexon CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
-
Publication number: 20140322753Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: June 30, 2014Publication date: October 30, 2014Inventors: Paul Harris, Elena Vlasenko, Marcus Sakari Kauppinnen, Elizabeth Zaretsky, Sarah Teter, Kimberly Brown
-
Patent number: 8871488Abstract: The present invention is related to recombinant host cells comprising: (i) at least one deletion, mutation, and/or substitution in an endogenous gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate or acetyl-CoA; and (ii) a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. The present invention is also related to recombinant host cells further comprising (iii) a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity.Type: GrantFiled: June 15, 2011Date of Patent: October 28, 2014Assignee: Butamax Advanced Biofuels LLCInventors: Michael Dauner, Lori Ann Maggio-Hall, Jean-Francois Tomb
-
Patent number: 8871489Abstract: This invention relates to the metabolic evolution of a microbial organism previously optimized for producing an organic acid in commercially significant quantities under fermentative conditions using a hexose sugar as sole source of carbon in a minimal mineral medium. As a result of this metabolic evolution, the microbial organism acquires the ability to use pentose sugars derived from cellulosic materials for its growth while retaining the original growth kinetics, the rate of organic acid production and the ability to use hexose sugars as a source of carbon. This invention also discloses the genetic change in the microorganism that confers the ability to use both the hexose and pentose sugars simultaneously in the production of commercially significant quantities of organic acids.Type: GrantFiled: November 17, 2010Date of Patent: October 28, 2014Assignee: Myriant CorporationInventors: Tammy Grabar, Wei Gong, R. Rogers Yocum
-
Publication number: 20140317786Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Inventor: Marc Morant
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140309232Abstract: The present invention relates to a bioengineering strain for production of novel microorganism-originated fungicides and uses thereof. The bioengineering strain for production of microorganism-originated fungicides of the present invention is obtained by transforming a phzH gene recombination expression plasmid into a strain producing phenazine-1-carboxylic acid, wherein the bioengineering strain produces phenazine-1-carboxamide. The present invention utilizes an existing strain producing phenazine-1-carboxylic acid to carry the phzH gene recombination expression plasmid, thereby achieving efficient expression of the phzH gene and transforming phenazine-1-carboxylic acid into phenazine-1-carboxamide. The present invention further discloses uses of the bioengineering strain, including a microorganism-originated fungicide produced by the bioengineering strain through fermentation, and preparation and application of the microorganism-originated fungicide.Type: ApplicationFiled: November 21, 2011Publication date: October 16, 2014Applicant: SHANGHAI JIAOTONG UNIVERSITYInventors: Yuquan Xu, Huifeng Shen, Ya-Wen He, Wanping Zhou
-
Publication number: 20140308717Abstract: The present invention relates to a method comprising the steps a) providing a secondary alcohol, b) oxidizing the secondary alcohol by contacting it with an NAD(P)+-dependent alcohol dehydrogenase and c) contacting the oxidation product of step a) with a transaminase, wherein the NAD(P)+-dependent alcohol dehydrogenase and/or the transaminase is a recombinant or isolated enzyme, to a whole cell catalyst for carrying out the method, and to the use of such a whole cell catalyst for oxidizing a secondary alcohol.Type: ApplicationFiled: July 27, 2012Publication date: October 16, 2014Applicant: Evonik Degussa GmbHInventors: Thomas Haas, Markus Poetter, Jan Christoph Pfeffer, Wolfgang Kroutil, Arne Skerra, Alexandra Lerchner, Katharina Christin Tauber, Johann H. Sattler, Steffen Schaffer
-
Publication number: 20140308700Abstract: Provided herein are polypeptides having hydrogenase activity. The polypeptide may be multimeric, and may have hydrogenase activity of at least 0.05 micromoles H2 produced min?1 mg protein?1. Also provided herein are polynucleotides encoding the polypeptides, genetically modified microbes that include polynucleotides encoding one or more subunits of the multimeric polypeptide, and methods for making and using the polypeptides.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: MICHAEL W.W. ADAMS, ROBERT C. HOPKINS, FRANCIS E. JENNEY, JR., JUNSONG SUN
-
Publication number: 20140304859Abstract: Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 14, 2012Publication date: October 9, 2014Applicant: Novozymes Inc.Inventors: Ye Liu, Yu Zhang, Junxin Duan, Lan Tang
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Patent number: 8852903Abstract: Recombinant microorganisms having an improved ability to co-metabolize in medium both fructose and glucose are described. The recombinant microorganisms comprise a promoter operably linked to a native or non-native nucleotide sequence that encodes a fucose: H+ symporter polypeptide. The recombinant microorganisms are useful for the production of a variety of products including glycerol and glycerol derivatives such as 1,3-propanediol and 3-hydroxypropionic acid.Type: GrantFiled: October 18, 2010Date of Patent: October 7, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Andrew C. Eliot, Anthony A. Gatenby, John S. Chapman
-
Publication number: 20140296505Abstract: The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation.Type: ApplicationFiled: February 20, 2014Publication date: October 2, 2014Applicants: Seikagaku Corporation, DSM IP ASSETS B.V.Inventors: Daniel H. DOHERTY, Craig A. WEAVER, Kentaro MIYAMOTO, Toshikazu MINAMISAWA
-
Publication number: 20140295502Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.Type: ApplicationFiled: May 13, 2014Publication date: October 2, 2014Inventors: Wu-Bo LI, Joel Jessee, Christian Gruber
-
Publication number: 20140298505Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: June 6, 2012Publication date: October 2, 2014Inventor: Ralf Kühn
-
Publication number: 20140287471Abstract: The present disclosure relates to variant CBH I polypeptides that have reduced product inhibition, and compositions, e.g., cellulase compositions, comprising variant CBH I polypeptides. The variant CBH I polypeptides and related compositions can be used in variety of agricultural and industrial applications. The present disclosure further relates to nucleic acids encoding variant CBH I polypeptides and host cells that recombinantly express the variant CBH I polypeptides.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Applicant: Bp Corporation North America Inc.Inventors: Sarah Richardson Hanson, Justin T. Stege, Cecilia Cheng, Peter Luginbuhl
-
Publication number: 20140286934Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.Type: ApplicationFiled: January 30, 2014Publication date: September 25, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
-
Publication number: 20140287465Abstract: The present invention relates to polypeptides having xylanase activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.Type: ApplicationFiled: December 18, 2012Publication date: September 25, 2014Inventors: Nikolaj Spodsberg, Tarana Shaghasi
-
Publication number: 20140289905Abstract: Provided are isolated polypeptides having xylanase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 9, 2012Publication date: September 25, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140273204Abstract: The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Publication number: 20140273129Abstract: Provided herein are glycerol-3-phosphate dehydrogenase (GPD) enzymes with increased KM for NADH and GPD enzymes with substantially the same affinity for NADH and NADPH and/or are feedback inhibited by glycerol-3-phosphate. Also provided herein are recombinant microorganisms comprising a heterologous gene encoding GPD and a deletion or disruption in an endogenous gene encoding GPD. Also provided are recombinant microorganisms comprising a heterologous gene encoding GPD and a butanol biosynthetic pathway. Further provided are methods of producing butanol comprising providing the recombinant microorganisms described herein and contacting the recombinant microorganism with at least one fermentable carbon substrate under conditions wherein butanol is produced.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: BUTAMAX ADVANCED BIOFUELS LLCInventors: Ritu Bhalla, Gopal K. Chotani, Michael Dauner, Mark J. Nelson, Daniel P. O'keefe, Caroline M. Peres, Jahnavi Chandra Prasad, Jean-Francois Tomb
-
Publication number: 20140273119Abstract: Provided are isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 30, 2012Publication date: September 18, 2014Inventors: Ye Liu, Lan Tang, Yu Zhang, Junxin Duan
-
Publication number: 20140273089Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: AMGEN, INC.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Publication number: 20140273161Abstract: The invention provides a system of heavy metal sequestration by bacteria. The bacteria expresses the ppk, mt, and/or ?-galactosidase (lacZ) genes and can tolerate at least 25 ?M mercury, 1,000 ?M zinc, 250 ?M cadmium, and 3,000 ?M Pb. The system allows for facile determination of the presence of heavy metal contaminants in a liquid and the facile collection of the bacteria that has sequestered large amounts of heavy metal. Further provided is a system of gene expression in bacteria that comprises phage and plastid gene expression elements and delivers a particularly high level of protein expression and heavy metal resistance.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Applicant: Inter American University of Puerto RicoInventor: Oscar N. Ruiz
-
Publication number: 20140255408Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.Type: ApplicationFiled: May 21, 2014Publication date: September 11, 2014Applicant: Janssen Biotech, Inc.Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
-
Publication number: 20140256904Abstract: The subject of the invention is a biotechnological process for the production of ?-functionalized carboxylic acids and of ?-functionalized carboxylate esters from simple carbon sources.Type: ApplicationFiled: August 15, 2012Publication date: September 11, 2014Applicant: Evonik Degussa GmbHInventors: Steffen Schaffer, Nicole Decker, Jasmin Gielen, Harald Haeger, Thomas Haas, Markus Poetter, Hans-Georg Hennemann, Mirja Wessel, Michael Volland
-
Publication number: 20140255997Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 11, 2012Publication date: September 11, 2014Inventors: Esben Peter Friis, Leonardo De Maria, Jesper Vind, Thomas A. Poulsen, Allan Svendsen, Steffen Danielsen, Rolf T. Lenhard, Henrik Friis-Madsen, Lars K. Skov
-
Publication number: 20140255410Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: September 11, 2014Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20140256930Abstract: An object of the present invention is to provide a method for converting the coenzyme dependency of enzymes of the medium-chain dehydrogenase/reductase (MDR) family. A further object of the present invention is to provide enzyme variants of the MDR family whose coenzyme dependency is converted by the conversion method and a method for enzymatically producing optically active alcohols using the enzymes. The present inventors developed a novel enzyme conversion method for converting the coenzyme dependency of enzymes of the MDR family, rationally designed enzyme variants that are altered by the enzyme conversion method to be able to use NADPH as a coenzyme from a useful enzyme of the MDR family that uses NADH as a coenzyme, and actually provide variants having such an ability.Type: ApplicationFiled: June 27, 2012Publication date: September 11, 2014Applicant: KANEKA CORPORATIONInventors: Shinichi Yoshida, Shunichi Taira, Masakatsu Nishihachijyo, Masutoshi Nojiri, Shigeru Kawano
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140248283Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: ALPER BIOTECH, LLCInventor: Özge Alper
-
Publication number: 20140248673Abstract: This document describes biochemical pathways for producing pimelic acid, 7-hydroxyheptanoic acid, 7-aminoheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the CoA-dependent elongation enzymes or analog enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.Type: ApplicationFiled: December 13, 2013Publication date: September 4, 2014Applicant: INVISTA North America S.á r.I.Inventors: Adriana Leonora Botes, Alex Van Eck Conradie
-
Publication number: 20140248663Abstract: Provided are isolated polypeptides having cellobiohydrolase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 15, 2012Publication date: September 4, 2014Inventors: Lan Tang, Junxin Duan, Yu Zhang, Ye Liu
-
Publication number: 20140234897Abstract: Disclosed are isolated polypeptides having cellobiohydrolase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Furthermore, nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains are disclosed.Type: ApplicationFiled: November 2, 2012Publication date: August 21, 2014Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140234907Abstract: Provided are isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: August 21, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Ye Liu, Junxin Duan, Lan Tang
-
Publication number: 20140234313Abstract: The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired VL and VH domains that demonstrate soluble expression and folding in a reducing or intracellular environment. The invention also relates to polynucleotides encoding such polypeptides, to libraries of such polypeptides or polynucleotides, and to methods of using such polypeptides in research, diagnostic and therapeutic applications.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Affinity Biosciences Pty LtdInventors: Matthew David Beasley, Keith Philip Niven, Ben Ross Kiefel
-
Publication number: 20140234304Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.Type: ApplicationFiled: March 31, 2014Publication date: August 21, 2014Applicant: Janssen Biotech, Inc.Inventors: Juan Carlos ALMAGRO, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou